Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.
about
Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium Growth Indicator Tube and a colorimetric methodDiscovery of novel MDR-Mycobacterium tuberculosis inhibitor by new FRIGATE computational screenEvaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic reviewFrom multidrug- to extensively drug-resistant tuberculosis: upward trends as seen from a 15-year nationwide studyFirst evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countriesQuantitative drug-susceptibility in patients treated for multidrug-resistant tuberculosis in Bangladesh: implications for regimen choice.Systematic analysis of pyrazinamide-resistant spontaneous mutants and clinical isolates of Mycobacterium tuberculosis.Real-time PCR using mycobacteriophage DNA for rapid phenotypic drug susceptibility results for Mycobacterium tuberculosis.Isothermal RNA sequence amplification method for rapid antituberculosis drug susceptibility testing of Mycobacterium tuberculosis.Molecular detection and characterization of resistant genes in Mycobacterium tuberculosis complex from DNA isolated from tuberculosis patients in the Eastern Cape province South Africa.Tuberculosis in the developing world: recent advances in diagnosis with special consideration of extensively drug-resistant tuberculosis.Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials.Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis.Rapid detection of rpoB mutations in rifampin resistant M. tuberculosis from sputum samples by denaturing gradient gel electrophoresisDiscordant resistance to kanamycin and amikacin in drug-resistant Mycobacterium tuberculosisCorrelating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables.Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment.Worldwide emergence of extensively drug-resistant tuberculosis.Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant TuberculosisRapid detection of Mycobacterium tuberculosis resistance to second-line drugs by use of the manual mycobacterium growth indicator tube system.Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays.Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: rapid, simple, and inexpensive method.Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid.Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation.Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis.Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin.Implications of Failure to Routinely Diagnose Resistance to Second-Line Drugs in Patients With Rifampicin-Resistant Tuberculosis on Xpert MTB/RIF: A Multisite Observational Study.Testing susceptibility of multidrug-resistant Mycobacterium tuberculosis to second-line drugs by use of blood agar.Establishment of an in vitro D-cycloserine-synthesizing system by using O-ureido-L-serine synthase and D-cycloserine synthetase found in the biosynthetic pathway.Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex.Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.
P2860
Q28365220-CDB0152C-7E4E-44EB-AFC0-B6CEB1096757Q28478254-EE46BF3E-5E8E-4D03-A264-CC1C6A9EC4C9Q28481845-2418106C-E896-44EF-97CE-7C349AD4BBC2Q28487902-E065CF17-A65F-4E28-896D-C9E07D67B9A9Q28534345-D7186E1C-147F-4474-9D6B-72408AAD04EAQ28543642-D2F4ADA7-AC45-4ED7-A4F6-8BC649A19CDAQ30419570-3C613BE6-9DDF-4A86-B17B-648A9A701B41Q30425212-4786C24F-DA19-4009-8336-554274434129Q33859255-187ECDBC-DA16-452C-B459-4F39ED254FACQ34169216-1E0BA1DE-A9D2-446E-A550-5D1D63D3D421Q34201423-53FBC293-C25F-4881-B6E9-66D50059E0C1Q34431677-47312A2B-F3E5-4774-9017-17D860C03893Q34431814-2933BBA6-4F79-4FC1-AF3A-8625AB9A1D7CQ35599028-57729088-503A-4785-BBE6-FEF6352CD6D1Q35673513-2FF9D557-51F6-40AE-80FC-7EEFBB1F8D56Q35685088-AA8D491C-021B-4BD0-91FC-1794A32E58D5Q36892368-DC38B399-48D2-45EF-9397-946ED9DCAF41Q36917933-913A053D-299C-4CFF-81DF-CEBED9959E19Q37274766-FDD3214F-4895-4382-8448-04815F129A28Q37302822-D768D439-7150-4EA7-A9CF-0FC1A626747CQ39030684-737BFBCA-7A58-4345-96F4-BD2C0EB509EFQ39218265-65A1630B-7907-4D2D-93B8-EAC52656ECE2Q39218305-ED3217E0-9BED-4796-B21B-8B940BC14A5BQ39218310-3FE4EBDC-C15D-4B51-8B8F-C825E95FCC14Q39652695-111EB469-E7DE-4FF0-A575-6234CF94F328Q39990545-2F6770E7-9D28-467E-B421-BC9998C73C06Q40209976-034AFF47-FC08-4151-8D15-A139E337EA19Q40279724-53629D0A-C996-41B7-A6F8-A80FD3EECEC4Q40332311-366DDAD7-9E3C-49CC-B4F5-C3A4183A69C9Q41826690-93313729-BFF7-4B0D-9922-6F746AED5B0FQ42110222-4362F199-760C-4767-919A-19EDB88F9E60Q42613641-329F4766-FCB3-44CD-A737-8617F8CFC5B8Q42715629-958459EE-0C23-4EC9-9191-7515598E4804Q50134142-2B9699A1-F9F7-404B-B12B-E7F6695E935D
P2860
Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Multicenter laboratory validat ...... rtion method with solid media.
@ast
Multicenter laboratory validat ...... rtion method with solid media.
@en
type
label
Multicenter laboratory validat ...... rtion method with solid media.
@ast
Multicenter laboratory validat ...... rtion method with solid media.
@en
prefLabel
Multicenter laboratory validat ...... rtion method with solid media.
@ast
Multicenter laboratory validat ...... rtion method with solid media.
@en
P2093
P2860
P1476
Multicenter laboratory validat ...... ortion method with solid media
@en
P2093
A Ebrahimzadeh
D A Bonato
G E Pfyffer
J Hotaling
J Kornblum
M Salfinger
P2860
P304
P407
P577
1999-10-01T00:00:00Z